Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: treace.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/16/2024 | $16.00 → $6.50 | Buy → Neutral | UBS |
5/8/2024 | $15.00 → $5.50 | Overweight → Equal-Weight | Morgan Stanley |
5/8/2024 | $17.00 → $7.00 | Buy → Hold | Truist |
5/8/2024 | $15.00 → $6.00 | Buy → Hold | Stifel |
5/8/2024 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
5/8/2024 | Buy → Neutral | BTIG Research | |
9/29/2023 | $24.00 | Buy | UBS |
5/1/2023 | $33.00 | Buy | Truist |
4/11/2023 | $26.00 | Equal-Weight | Stephens |
5/12/2022 | $22.00 | Buy | BTIG Research |
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
UBS downgraded Treace Medical Concepts from Buy to Neutral and set a new price target of $6.50 from $16.00 previously
Morgan Stanley downgraded Treace Medical Concepts from Overweight to Equal-Weight and set a new price target of $5.50 from $15.00 previously
Truist downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $7.00 from $17.00 previously
Stifel downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $6.00 from $15.00 previously
JP Morgan downgraded Treace Medical Concepts from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously
BTIG Research downgraded Treace Medical Concepts from Buy to Neutral
UBS initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $24.00
Truist initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $33.00
Stephens initiated coverage of Treace Medical Concepts with a rating of Equal-Weight and set a new price target of $26.00
BTIG Research initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $22.00
PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts. "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou
PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit
PONTE VEDRA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022. "With decades of combined experience leading medical device companies, Lance and Jane strengthen the expertise of our Company's board of directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board look forward to their support and guidance through our next phase of grow
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, beginning at approximately 10:00 am ET. A live webcast and replay of the fireside chat will be available on the Company's investors relations w
PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue of $44.5 million in second quarter 2024 increased 6% over same period in 2023Gross margin of 80.2% in second quarter 2024Patent portfolio expands to 65 granted U.S. patents, with an additional 22 granted patents worldwide and 84 pending U.S. patent applications John T. Treace
PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbe
PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:00 am Eastern Time. A live webcast and replay of the fireside chat will be available on the Company's investor relations website at https://i
PONTE VEDRA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023Gross margin of 80.2% in first quarter 2024First quarter 2024 net loss attributable to common stockholders was ($18.7) million compared to ($13.5) million for same period in 2023Adjusted EBITDA loss im
DALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Treace Medical has been named the first Medical Device Partner and Official Foot and Ankle Solution Partner for the PPA Tour. Treace was the first medical device company to become a PPA sponsor at last year's National Championships. Beginning with the Fanatics Sportsbook North Carolina Cup presented by CIBC earlier this
PONTE VEDRA, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Bank of America Health Care Conference on Wednesday, May 15, 2024, beginning at approximately 2:20 pm PT. A live webcast and replay of the fireside chat will be available on the Company's investor relations website at https://invest
PONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the first-ever National Bunion Day in the United States. National Bunion Day is an opportunity to help more people learn about the identification and treatment of this common bone deformity in the foot, which often includes debilitating pain for millions of adults in the U.S. Approximately one in four U.S. adults alone develop the bunion deformity in their lifeti
PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in number
Treace Further Expands Focus on Bunion Deformity Education by Sponsoring First-Ever National Bunion Day in the U.S. on April 16, 2024 Launches New "Future You" Patient Education and Brand Awareness Campaign PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that 100,000 patients have been treated with its patented Lapiplasty® 3D Bunion Correction® System.1 This milestone coincides with the f
PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbe
PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in number
PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rece
PONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results. Highlights: Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022. Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increas
PONTE VEDRA, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Thursday, November 9, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin
PONTE VEDRA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived we
PONTE VEDRA, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Monday, May 8, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to joi
PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a
PONTE VEDRA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full year grow
PONTE VEDRA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived w
10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
DEF 14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
DEFA14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
ARS - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
10-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
Treace Medical Concepts (NASDAQ:TMCI) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 5 0 0 Analysts have set 12-month price targets for Treace Medical Concepts, revealing an average target of $8.25, a high estimate of $16.00, and a low estimate of $5.50. Observing a downward trend,
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $7 to $9.
Morgan Stanley analyst Drew Ranieri maintains Treace Medical Concepts (NASDAQ:TMCI) with a Equal-Weight and raises the price target from $5.5 to $8.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Treace Medical Concepts, Inc. (NASDAQ:TMCI) On May 7, Treace Medical Concepts reported first-quarter financial results and is
Analysts' ratings for Treace Medical Concepts (NASDAQ:TMCI) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 5 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 4 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.17, a high estimate of $16.00, and a low estimate of $5.50. A negative shift in sentiment is evident as analysts have decreased
UBS analyst Danielle Antalffy downgrades Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral and lowers the price target from $16 to $6.5.
- Conf Call
Orthopedic medical device company Treace Medical Concepts Inc (NASDAQ:TMCI) on Tuesday reported a first-quarter EPS loss of $(0.30), down from $(0.23) a year ago, better than the consensus of $(0.31). The company reported sales of $51.11 million, up 21%, beating the consensus of $49.1 million. The increase was driven by a higher volume of procedure kits sold due to an expanded surgeon customer base and a product mix shift that resulted from increased adoption of newer technologies and increased sales of complementary products used in bunion and related midfoot procedures. Guidance: Treace Medical Concepts cut its fiscal year 2024 sales guidance to $201 million-$211 million, down fro
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 150 points on Wednesday. The Dow traded up 0.41% to 39,042.68 while the NASDAQ fell 0.17% to 16,304.23. The S&P 500 also rose, gaining, 0.01% to 5,187.80. Check This Out: Top 2 Financial Stocks That May Fall Off A Cliff In May Leading and Lagging SectorsUtilities shares rose by 0.8% on Wednesday. In trading on Wednesday, real estate shares fell by 0.9%. Top Headline Emerson Electric Co (NYSE:EMR) posted better-than-expected results for its second quarter. Emerson Electric reported second-quarter FY24 net sales growth of 17% Y/Y to $4.38 billion, beating the consensus of $4.29 billio
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estimates. Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to Benzinga Pro. Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million. Upstart shares dipped 10.3% to $21.96 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Reborn Coffee, In